SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Charles Salski who wrote (1371)1/16/2000 9:21:00 PM
From: Sean Janzen  Read Replies (3) of 1501
 
It's just wild speculation on my part that something like this could happen. If IZP could issue 5-10 million shares at $6-10US then IZP would be a lot less dependant on big pharmas and would have cash to advance its potential fast track drug, IPL-423,323 for transplant, to market.

As for too many shares outstanding, Amgen has sales of $2.41 billion and 1.02 billion shares outstanding biz.yahoo.com. It is not inconceivable that IZP's sales could someday top $2.5 billion in sales. We have a lot of room for stock splits etc.

If the IPO market is hot for biotechs then lets do it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News